



MEMORANDUM

DATE: May 26, 2025

RE: M. tuberculosis PZA testing halt notice

Dear BC colleagues,

We would like to inform you that effective immediately, the BCCDC PHL TB/Mycobacteriology laboratory is **temporarily suspending phenotypic susceptibility testing of *Mycobacterium tuberculosis* to Pyrazinamide (PZA)** due to a **recall of the BD BACTEC MGIT 960 PZA kit (Cat. #245128)**. This recall affects multiple lots distributed between September 24, 2024, and April 7, 2025, which are reported to intermittently yield false-resistant PZA results. Susceptible results are not impacted.

The BCCDC PHL TB/Mycobacteriology laboratory has reviewed all *M. tuberculosis* isolates tested with affected kits and identified 62 cases. All had concordant genotypic and phenotypic results, including 14 PZA-resistant (4 *M. tuberculosis*, 10 *M. bovis* BCG) and 48 PZA-susceptible *M. tuberculosis* isolates. Based on this review, individual provider notifications will not be issued. However, please contact us if you have questions regarding your patients.

BD has not provided a timeline for kit replacement. In the interim, the BCCDC PHL TB/Mycobacteriology laboratory **will continue reporting PZA resistance predictions based on *pncA* genotypic analysis for all cultured *M. tuberculosis* complex organisms.**

This recall **does not affect phenotypic testing of other first- or second-line *M. tuberculosis* drugs.** For any inquiries, please contact the BCCDC PHL TB/Mycobacteriology laboratory Program Head.

Sincerely,

Linda M. N. Hoang, MSc, MD, DTM&H, FRCPC
Medical Microbiologist & Medical Director
BCCDC Public Health Laboratory

Inna Sekirova, MD, PHD, D(ABMM), FRCPC
Medical Microbiologist & Program Head
Mycobacteriology Laboratory
BCCDC Public Health Laboratory